Takeda Pharmaceutical Company Limited
TAK
$14.16
$0.443.21%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 958.61M | 709.46M | 1.37B | 1.93B | 974.51M |
| Total Depreciation and Amortization | 4.76B | 4.73B | 4.79B | 4.83B | 4.80B |
| Total Amortization of Deferred Charges | 265.19M | 265.19M | 219.53M | 219.53M | 219.53M |
| Total Other Non-Cash Items | 744.07M | 899.84M | 268.33M | -150.72M | 100.73M |
| Change in Net Operating Assets | 629.75M | 348.59M | 729.73M | -977.07M | -760.06M |
| Cash from Operations | 7.36B | 6.96B | 7.38B | 5.85B | 5.34B |
| Capital Expenditure | -1.28B | -1.32B | -1.30B | -1.32B | -1.25B |
| Sale of Property, Plant, and Equipment | 44.67M | 515.30K | 318.80K | 2.08M | 59.52M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 319.28M | 135.34M | 195.38M | 187.12M | 150.82M |
| Other Investing Activities | -705.69M | -1.22B | -1.58B | -1.30B | -1.31B |
| Cash from Investing | -1.62B | -2.40B | -2.68B | -2.43B | -2.35B |
| Total Debt Issued | 727.87B | 1.05T | 1.02T | 1.15T | 674.64B |
| Total Debt Repaid | -1.47T | -1.37T | -1.15T | -732.18B | -342.88B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -101.58B | -51.86B | -1.88B | -1.88B | -1.88B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.09B | -1.97B | -1.96B | -1.95B | -1.95B |
| Other Financing Activities | -127.54B | -82.75B | -79.00B | -72.36B | -15.58B |
| Cash from Financing | -8.51B | -4.99B | -3.40B | 234.87M | 1.59M |
| Foreign Exchange rate Adjustments | -211.61M | -84.27M | 50.52M | -120.61M | 188.20M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | 6.90K |
| Net Change in Cash | -2.99B | -517.05M | 1.34B | 3.53B | 3.18B |